Alnylam Pharmaceuticals, Inc. (ALNY) Posts Wider than Expected Q2 Loss
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $251.65 +3.00%
Revenue Growth %: +15.3%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
NEOV, MANU, CTAS, More
Revenue Growth %: +15.3%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $20.81 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Orosur Mining launches private placement targeting C$14M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
